ISAB: Operating result up 24% year-over-year, but sales and order intake declined

About this update from Inhalation Sciences Sweden Ab

Operating result improved 24% year-over-year, but sales and order intake declined amid a cautious life science market. The FDA collaboration and new partnerships are expected to drive future growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Inhalation Sciences Sweden Ab